Prognosis of Patients with Cirrhosis and Ascites

Ascites and Renal Dysfunction in Liver Disease: Pathogenesis, Diagnosis, and Treatment: Second Edition

Volumn , Issue , 2007, Pages 260-270

  Guevara, Mónica ^a   Cárdenas, Andrés ^b   Uríz, Juan ^c   Ginès, Pere ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c Instituto de Investigación Sanitaria de Navarra   (Spain)

Author keywords

Ascites; Cirrhosis; Glomerular filtration rate (GFR); Hepatic encephalopathy; Spontaneous bacterial peritonitis

Indexed keywords

EID: 84889400912     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470987476.ch21     Document Type: Chapter

References (64)

1. Saunders JB, Walters JRF, Davies P, Paton A. A 20-year prospective study of cirrhosis. Brit Med J 1981; 282:263-6.
2. Ginès P, Quintero E, Arroyo V et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology 1987; 7:122-8.
3. Planas R, Balleste B, Alvarez MA et al. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. J Hepatol 2004; 40:823-30.
4. Powel WJ, Klatskin G. Duration of survival in patients with Laennec's cirrhosis. Am J Med 1968; 44:406-20.
5. D'Amico G, Morabito A, Pagliaro L et al. Survival and prognostic indicators in compensated and decompensated cirrhosis. Dig Dis Sci 1986; 31:1507-13.
6. Salerno F, Borroni G, Moser P et al. Survival and prognostic factors of cirrhotic patients with ascites: a study of 134 patients. Am J Gastroenterol 1993; 88:514-19.
7. Fernandez-Esparrach G, Sanchez-Fueyo A, Ginès P et al. A prognostic model for predicting survival in cirrhosis with ascites. J Hepatol 2001; 34:46-52.
8. Llach J, Ginès P, Arroyo V et al. Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology 1988; 94:482-7.
9. Guardiola J, Baliellas C, Xiol X et al. External validation of a prognostic model for predicting survival of cirrhotic patients with refractory ascites. Am J Gastroenterol 2002; 97:2374-8.
10. Kamath PS, Wiesner RH, Malinchoc M et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33:464-70.
11. Tanaka R, Itoshima T, Nagashima H. Follow-up study of 582 liver cirrhosis patients for 26 years in Japan. Liver 1987; 31:468-75.
12. Zoli M, Cordiani MR, Marchesini G et al. Prognostic indicators in compensated cirrhosis. Am J Gastroenterol 1991; 86:1507-13.
13. DeJongh FE, Janssen HLA, DeMan RA et al. Survival and prognostic indicators in hepatitis B antigen-positive cirrhosis of the liver. Gastroenterology 1992; 103:1630-5.
14. Realdi D, Fattovich G, Hadziyannis S et al. Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. J Hepatol 1994; 21:656-66.
15. Fattovich G, Giustina G, Degos F et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112:463-72.
16. Fattovich G, Pantalena M, Zagni I et al. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol 2002; 97:2886-95.
17. Benvegnu L, Gios M, Bocatto S, Alberti A. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut 2004; 53:744-9.
18. Castells A, Salo J, Planas R et al. Impact of shunt surgery for variceal bleeding in the natural history of ascites in cirrhosis: a retrospective study. Hepatology 1994; 20:584-91.
19. Sanyal A, Freedman A, Luketic V et al. The natural history of portal hypertension after transjugular intrahepatic portosystemic shunts. Gastroenterology 1997; 112:889-98.
20. Morali GA, Sniderman KW, Deitel KM et al. Is sinusoidal portal hypertension necessary for the development of hepatic ascites? J Hepatol 1992; 16:249-50.
21. Abraldes JG, Tarantini I, Turnes J et al. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology 2003; 37:902-8.
22. Arroyo V, Ginès P, Gerbes AL et al. Defi nition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996; 23:164-76.
23. Ginès P, Arroyo V, Vargas V et al. Paracentesis with intravenous infusion of albumin as compared with peritoneovenous shunting in cirrhosis with refractory ascites. N Engl J Med 1991; 325:829-35.
24. Ginès A, Planas R, Angeli P et al. Treatment of patients with cirrhosis and refractory ascites by LeVeen shunt with titanium tip. Comparison with therapeutic paracentesis. Hepatology 1995; 22:124-31.
25. Ginès P, Uriz J, Calahorra B et al. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 2002; 123:1839-47.
26. Sanyal AJ, Genning C, Reddy KR et al. North American Study for the Treatment of Refractory Ascites Group. The North American Study for the Treatment of Refractory Ascites. Gastroenterology 2003; 124:634-41.
27. Friedman LS, Martin P, Munoz S. Liver function tests and the objective evaluation of the patient with liver disease. In: Zakim D, Boyer TD, eds. Hepatology. A Textbook of Liver Disease. Philadelphia: WB Saunders, 1996; 791-832.
28. Schlichting P, Christensen E, Andersen PK et al. Prognostic factors in cirrhosis identifi ed by Cox's regression model. Hepatology 1983; 3:889-95.
29. Poynard T, Zourabichvili O, Hilpert G et al. Prognostic value of total serum bilirubin/gamma glutamyl transpeptidase ratio in cirrhotic patients. Hepatology 1984; 4:324-7.
30. Mannes GA, Thieme C, Stellard F et al. Prognostic signifi cance of serum bile acids in cirrhosis. Hepatology 1986; 6:50-3.
31. Sugimura T, Tsuji Y, Sakamoto M et al. Long-term prognosis and prognostic factors of liver cirrhosis in the 1980's. J Gastroenterol Hepatol 1994; 9:154-61.
32. Afdhal N, Nunes D. Evaluation of liver fi brosis: a concise review. Am J Gastroenterol 2004; 99:1160-74.
33. Tage-Jensen U, Henriksen JH, Christensen E et al. Plasma catecholamine level and portal venous pressure as guides to prognosis in patients with cirrhosis. J Hepatol 1988; 6:350-8.
34. Christensen E, Schlichting P, Fauerholdt L et al. Changes of laboratory values with time in cirrhosis: prognostic and therapeutic signifi cance. Hepatology 1983; 3:889-95.
35. Parés A, Rodés J. Natural history of primary biliary cirrhosis. Clin Liver Dis 2003; 7:779-94.
36. Kim WR, Poterucha JJ, Wiesner RH et al. The relative role of the Child-Pugh classifi cation and the Mayo natural history model in the assessment of survival in patients with primary sclerosing cholangitis. Hepatology 1999; 29: 1643-8.
37. Hecker R, Sherlock S. Electrolyte and circulatory changes in terminal liver failure. Lancet 1956; 1:1121-5.
38. Arroyo V, Hecker R, Sherlock S. Electrolyte and circulatory changes in terminal liver failure. J Hepatol 2002; 36:315-20.
39. Arroyo V, Bosch J, Gaya J et al. Plasma renin activity and urinary sodium excretion as prognostic indicators in nonazotemic cirrhosis with ascites. Ann Intern Med 1981; 94:198-201.
40. Genoud E, Gonvers JJ, Schaller MD, Essinger A, Haller E, Brunner HR. Valeur pronostique du système rénine-angiotensine dans la réponse à la restriction sodée et le pronostic de l'ascite cirrhotique d'origine alcoolique. Schweiz Med Wochenschr 1986; 116:463-9.
41. Shear L, Kleinerman J, Gabuzda GJ. Renal failure in patients with cirrhosis of the liver. I Clinical and pathological characteristics. Am J Med 1965; 39:184-98.
42. Cosby RL, Yee B, Schrier RW. New classifi cation with prognostic value in cirrhotic patients. Miner Electrolyte Metab 1989; 15:261-6.
43. Arroyo V, Rodés J, Gutiérrez-Lizarraga MA et al. Prognostic value of spontaneous hyponatremia in cirrhosis with ascites. Am J Dig Dis 1976; 21:249-56.
44. Porcel A, Diaz F, Rendon P et al. Dilutional hyponatremia in patients with cirrhosis and ascites. Arch Intern Med 2002; 162:323-8.
45. Cardenas A, Uriz J, Ginès P, Arroyo V. Hepatorenal syndrome. Liver Transplantation 2000; 6 (Suppl. 1):S63-71.
46. Ginès P, Cárdenas A, Schrier R. Liver dsease and the kidney. In: Schrier R, ed. Diseases of the Kidney and Urinary Tract, 7th edn. Philadelphia: Lippincott Williams & Wilkins, 2001; 2167-203.
47. Maroto A, Ginès A, Salo J et al. Diagnosis of functional renal failure of cirrhosis by Doppler sonography. Prognostic value of resistive index. Hepatology 1994; 20:839-44.
48. Platt JF, Ellis JH, Rubin JM et al. Renal duplex Doppler ultrasonography: a noninvasive predictor of kidney dysfunction and hepatorenal failure in liver disease. Hepatology 1994; 20:362-9.
49. Hoeper MM, Krowka MJ, Strassburg CP. Portopulmonary hypertension and hepatopulmonary syndrome. Lancet 2004; 363:1461-8.
50. Schenk P, Schoniger-Hekele M, Fuhrmann V. Prognostic signifi cance of the hepatopulmonary syndrome in patients with cirrhosis. Gastroenterology 2003; 125:1042-52.
51. Christensen E. Prognostic models including the Child-Pugh, MELD and Mayo risk scores. Where are we and where should we go? J Hepatol 2004; 41;344-50.
52. Child III CG, Turcotte JG. Surgery and portal hypertension. In: Child III CG, ed. The Liver and Portal Hypertension. Philadelphia: WB Saunders, 1964; 50-6.
53. Pugh RNH, Murray-Lyon IM, Dawson JL et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60:646-9.
54. Christensen E, Schlingting P, Fauerholdt L et al. Prognostic value of Child-Turcotte criteria in medically treated cirrhosis. Hepatology 1984; 4:430-5.
55. Propst A, Propst T, Zangerl G et al. Prognosis and life expectancy in chronic liver disease. Dig Dis Sci 1995; 40:1805-15.
56. Botero RC, Lucey MR. Organ allocation: model for endstage liver disease, Child-Turcotte-Pugh, Mayo risk score, or something else. Clin Liver Dis 2003; 7:715-27.
57. Malinchoc M, Kamath P, Gordon F et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000; 31:864-71.
58. Wiesner RH, McDiarmid SV, Kamath P et al. MELD and PELD: application of survival models to liver allocation. Liver Transplant 2001; 7:567-80.
59. Wiesner R, Edwards E, Freeman R et al. Model for end stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003; 124:91-6.
60. Botta F, Giannini E, Romagnoli P et al. Meld scoring system is useful in predicting prognosis in patients with liver cirrhosis and is correlated with residual liver function: a European study. Gut 2003; 52:134-9.
61. Everson GT. MELD: The answer or just more questions? Gastroenterology 2003; 124:251-4.
62. Heuman DM, Abou-assi SG, Habib A et al. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology 2004; 40:802-10.
63. Biggins S, Rodriguez HJ, Bachetti P, Bass NM, Robert JP, Terrault NA. Serum sodium predicts mortality in patients listed for liver transplantation. Hepatology 2004; 41:32-9.
64. Sort P, Navasa M, Arroyo V et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med 1999; 5:403-9.